Market Trends of Global Atherosclerosis Drugs Industry
This section covers the major market trends shaping the Atherosclerosis Drugs Market according to our research experts:
Cholesterol Lowering Medications Segment is Dominating the Atherosclerosis Drugs Market.
Cholesterol-lowering drugs include statins and fibrates. According to World Health Organization (WHO) 2022, raised cholesterol is estimated to cause 2.6 million deaths (4.5% of total) and 29.7 million Disability-adjusted life years (DALYs), or 2% of total DALYS. Raised total cholesterol is a major cause of disease burden in both the developed and developing world as a risk factor for ischemic heart disease and stroke. The dominant share of the segment is attributed to the increasing prevalence of cardiovascular disease and high cholesterol, and obesity globally. For instance, according to the World Health Organization 2022, an estimated 39 million children under the age of 5 were overweight or obese in 2020. Similarly, according to the World Health Organization (WHO) 2022, cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. CVDs are a group of disorders of the heart and blood vessels and include coronary heart disease, cerebrovascular disease, rheumatic heart disease, and other conditions. A heightened intake of energy-dense foods that are high in fat and sugars, and an upsurge in physical immobility due to the increasingly inactive nature of many forms of work, changing modes of transportation, and increasing urbanization are factors propelling the high cholesterol rates and ultimately boosting the segment growth.
Furthermore, the approval of novel cholesterol-reducing drugs is enhancing segment growth. For instance, the drugs, alirocumab (Praluent) and evolocumab (Repatha) belong to a new category of medications known as PCSK9 inhibitors which lower harmful LDL cholesterol values dramatically more than 50%. these types of novel treatment drugs boost segment growth. The increasing patient pool and increasing approvals of new drugs enhance the segment growth.
North America is Expected to Hold a Significant Share in the Market and is expected to do the same in the Forecast Period
North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, high prevalence of cardiovascular diseases and atherosclerosis, and established healthcare infrastructure are some of the key factors accountable for its large share in the market. According to National Center for Chronic Disease Prevention and Health Promotion, Division for Heart Disease and Stroke Prevention, data was updated in July 2022, 1 person dies every 34 seconds in the United States from cardiovascular disease. About 697,000 people in the United States died from heart disease in 2020, that's 1 in every 5 deaths. Similarly, according to National Center for Chronic Disease Prevention and Health Promotion, Division for Heart Disease and Stroke Prevention, data updated in July 2022, nearly 94 million United States adults aged 20 or older have total cholesterol levels higher than 200 mg/dL and around 28 million adults in the United States have total cholesterol levels higher than 240 mg/dL. As per the same source, around 7% of United States children and adolescents ages 6 to 19 have high total cholesterol. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth. In this region the United States has the maximum share due to supportive healthcare policies, a high number of patients, and a developed healthcare market. Hence, these aforementioned factors are expected to boost the market growth in the region.
